Journal
FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.633430
Keywords
homeobox A5; glioma; cell cycle; cell proliferation; prognosis
Categories
Funding
- Hunan Provincial Natural Science Foundation of China [2018JJ3838]
- China Postdoctoral Science Foundation [2018M633002]
- Hunan Provincial Health Committee Foundation of China [C2019186]
- Xiangya Hospital Central South University postdoctoral foundation
Ask authors/readers for more resources
The study identified HOXA5 as a key factor in glioma cell proliferation, where high expression is associated with unfavorable clinical features and worse clinical outcomes. Differences in CNVs and SNPs profiles further confirmed its role in glioma aggressiveness.
Glioma is malignant tumor derives from glial cells in the central nervous system. High-grade glioma shows aggressive growth pattern, and conventional treatments, such as surgical removal and chemo-radiotherapy, archive limitation in the interference of this process. In this work, HOXA5, from the HOX family, was identified as a glioma cell proliferation-associated factor by investigating its feature in the TCGA and CGGA data set. High HOXA5 expression samples contain unfavorable clinical features of glioma, including IDH wild type, un-methylated MGMT status, non-codeletion 1p19q status, malignant molecular subtype. Survival analysis indicates that high HOXA5 expression samples are associated with worse clinical outcome. The CNVs and SNPs profile difference further confirmed the enrichment of glioma aggressive related biomarkers. In the meantime, the activation of DNA damage repair-related pathways and TP53-related pathways is also related to HOXA5 expression. In cell lines, U87MG and U251, by interfering HOXA5 expression significantly inhibit glioma progression and apoptosis, and cell cycle is arrested at the G2/M phase. Collectively, increased HOXA5 expression can promote glioma progression via affecting glioma cell proliferation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available